Why the study?
Does intensive lipid-lowering therapy with strong statins and the addition of ticlopidine prevent saphenous vein graft disease (yellow plaque and thrombi) after CABG?
Does intensive lipid-lowering therapy with strong statins and the addition of ticlopidine prevent saphenous vein graft disease (yellow plaque and thrombi) after CABG?
Intensive lipid-lowering therapy with strong statins and the addition of ticlopidine to aspirin may prevent the development of yellow plaque and thrombi in saphenous vein grafts after CABG.
Should not yet change post-CABG SVG management; leaves open whether intensive statins plus ticlopidine prevent graft plaque and thrombi.
Background: We made a long-term assessment of saphenous vein graft (SVG) neo-intima after coronary bypass (CABG) using intracoronary angioscopy. Methods: Seventy-eight SVGs from 78 patients were assessed after CABG. The patients were divided into two groups: group I consisted of 34 patients whose SVG had yellow plaque of more than grade II; group II consisted of 44 patients whose SVG neo-intima was clear white. Follow-up duration, serum lipid level, type of statin and anti-thrombus drugs, among other factors, were compared between the groups. Results: Age, sex, prevalence of coronary risk factors, and follow-up duration were similar. The serum LDL level (I: 122.3±56.3 vs II: 85.8±26.1 mg/dl) and LDL/HDL ratio (I: 2.93±1.37 vs II: 1.68±0.69) were significantly higher in group I than in group II, whereas the serum HDL level (I: 43.4±11.5 vs II: 54.1±15.3 mg/dl) was significantly lower in group I (P=0.0003) than in group II. More than 85% of patients in both groups received statin therapy, but 88.2% of group I patients were administered a mild statin, whereas 95.5% of group II patients were administered a strong statin. All patients were under aspirin therapy, but additional ticlopidine was prescribed to significantly more patients in group II (I: 14.7% vs II: 70.5%, P<0.0001). On the other hand, additional warfarin therapy was administered significantly more in group I (I: 29.4% vs II: 0.4%, P=0.0351). The incidence of floating white thrombi was significantly higher in group I (I: 27 SVGs, 81.8% vs II: 4 SVGs, 10%, P<0.0001). Conclusion: Intensive lipid-lowering therapy with strong statins could be quite an attractive method of avoiding post-CABG SVG disease. Ticlopidine in addition to aspirin therapy inhibited SVG thrombi, but warfarin had no effect.
No takes yet. Share an insight, caveat, or question.
Hata et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: